Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 939 participants.
Also called NCT02471404
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 939 participants
- Sponsor
- Registry
-
NCT02471404
-
- Other papers using this trial's data
- Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Czechia, Germany, Hungary, Poland, Slovakia
- Registry status
- Completed
Technical summary
Registry record NCT02471404. Randomized; triple masking; primary purpose treatment. Start 2015-09-21 (actual); primary completion 2017-03-13 (actual). Results posted on 2019-03-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Inadequate Glycaemic Control
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Saxagliptin
- Intervention (Drug)
- Glimepiride
- Intervention (Drug)
- Placebo for dapagliflozin
- Intervention (Drug)
- Placebo for saxagliptin
- Intervention (Drug)
- Placebo for glimepiride
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02471404- Content hash
f08efcc5f28f170dd8f510cf562231bc5923e9750e769c473cfef8fd4e1e91ad